EN | DE

Dr Chantal Bader

About

Chantal Bader studied pharmacy at the Ruprecht-Karls-University in Heidelberg. In 2016, she joined Rolf Müllers group at the HIPS, where she received her diploma for her thesis on bioactivity-guided isolation and structure elucidation of novel natural products from myxobacteria. After receiving her approbation in 2016, Chantal continued her research in Rolf Müllers group, where she currently works as a PhD student. 
Chantal Bader’s work mainly focuses on method development for myxobacterial metabolomics. This includes evaluating the impact of state-of-the-art analytical techniques like FT-ICR and UHPLC-timsTOF for expanding the scope of detectable metabolites. For the isolation, characterization and de novo structure elucidation of novel natural products, she is also working with supercritical-fluid extraction and chromatography (SFE/SFC), as well as reversed-phase chromatography and high resolution NMR-spectroscopy.
 


2021

Improved broad-spectrum antibiotics against Gram-negative pathogens via darobactin biosynthetic pathway engineering

Groß S, Panter F, Pogorevc D, Seyfert C, Deckarm S, Bader C, Herrmann J, Müller R (2021)

Chemical ScienceDOI: 10.1039/d1sc02725e

Sesbanimide R, a Novel Cytotoxic Polyketide Produced by Magnetotactic Bacteria

Awal R, Haack P, Bader C, Riese C, Schüler D, Müller R (2021)

mBio 12 (3)DOI: 10.1128/mBio.00591-21

Search for the Active Ingredients from a 2-Aminothiazole DMSO Stock Solution with Antimalarial Activity

Ropponen H, Bader C, Diamanti E, Illarionov B, Rottmann M, Fischer M, Witschel M, Müller R, Hirsch A (2021)

ChemMedChemDOI: 10.1002/cmdc.202100067

Synergizing the potential of bacterial genomics and metabolomics to find novel antibiotics

Panter F, Bader C, Müller R (2021)

Chemical ScienceDOI: 10.1039/d0sc06919a

The sandarazols are cryptic and structurally unique plasmid encoded toxins from a rare myxobacterium

Panter F, Bader C, Müller R (2021)

Angewandte Chemie (International ed. in English)DOI: 10.1002/anie.202014671

Expanding the Scope of Detectable Microbial Natural Products by Complementary Analytical Methods and Cultivation Systems

Bader C, Haack P, Panter F, Krug D, Müller R (2021)

Journal of natural productsDOI: 10.1021/acs.jnatprod.0c00942

2020

Supercritical Fluid Extraction Enhances Discovery of Secondary Metabolites from Myxobacteria

Bader C, Neuber M, Panter F, Krug D, Müller R (2020)

Analytical chemistryDOI: 10.1021/acs.analchem.0c02995

In depth natural product discovery - Myxobacterial strains that provided multiple secondary metabolites

Bader C, Panter F, Müller R (2020)

Biotechnol Adv. 39DOI: 10.1016/j.biotechadv.2019.107480

2019

Synthesis of New Cyclomarin Derivatives and Their Biological Evaluation towards Mycobacterium Tuberculosis and Plasmodium Falciparum

Kiefer A, Bader C, Held J, Esser A, Rybniker J, Empting M, Müller R, Kazmaier U (2019)

Chem. Eur. J. 25 (37): 8894-8902DOI: 10.1002/chem.201901640

Engineering Atypical Tetracycline Formation in Amycolatopsis sulphurea for the Production of Modified Chelocardin Antibiotics

Lukežic T, Fayad A, Bader C, Harmrolfs K, Bartuli J, Groß S, Lešnik U, Hennessen F, Herrmann J, Pikl Š, Petkovic H, Müller R (2019)

ACS Chem. Biol. 14 (3): 468-477DOI: 10.1021/acschembio.8b01125

2018

Concepts and Methods to Access Novel Antibiotics from Actinomycetes

Hug J, Bader C, Remškar M, Cirnski K, Müller R (2018)

Antibiotics 7 (2)DOI: 10.3390/antibiotics7020044